Ignite Creation Date:
2024-05-06 @ 5:56 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05483257
Status:
COMPLETED
Last Update Posted:
2022-08-02
First Post:
2022-07-29
Brief Title:
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Sponsor:
BAIYONG SHEN
Organization:
Ruijin Hospital
Study Overview
Official Title:
Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma A Retrospective Observational Cohort Study
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pancreatic adenocarcinoma PAAD patients following surgeries are prone to relapse shortly while it is not well understood by current biomarkers Given the potential associations of human leukocyte antigen class I HLA-I genotype with oncogenic mutational profile and immunotherapy efficacy we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None